HYDROCODONE BITARTRATE AND
This product contains hydrocodone (dihydrocodeinone) bitartrate, a semisynthetic centrally acting narcotic antitussive. Homatropine methylbromide is included in a subtherapeutic amount to discourage deliberate overdosage. Each 5 mL (one teaspoonful) contains:
Hydrocodone Bitartrate........................ 5 mg
Homatropine Methylbromide............... 1 . 5 mg
Hydromet (hydrocodone/homatropine) is indicated for the following:
For the symptomatic relief of cough.
Media Articles Related to Hydromet (Hydrocodone / Homatropine)
Whooping cough vaccine not associated with preterm delivery
Source: Pregnancy / Obstetrics News From Medical News Today [2014.11.12]
New research has found that the Tdap vaccine recommended to protect newborns from pertussis is not associated with an increased risk of preterm delivery or small birth sizes.
Whooping Cough Vaccine Seems Safe in Pregnancy, Study Finds
Source: MedicineNet Chronic Cough Specialty [2014.11.12]
Title: Whooping Cough Vaccine Seems Safe in Pregnancy, Study Finds
Category: Health News
Created: 11/11/2014 12:00:00 AM
Last Editorial Review: 11/12/2014 12:00:00 AM
Placebos are 'more effective than no treatment' for children's coughs
Source: Complementary Medicine / Alternative Medicine News From Medical News Today [2014.10.28]
Both agave nectar and a placebo were more effective at reducing cough symptoms among children under 2 years than watchful waiting, according to a new study.
Placebo Treatment May Quiet Kids' Cough
Source: MedicineNet Botulism Specialty [2014.10.28]
Title: Placebo Treatment May Quiet Kids' Cough
Category: Health News
Created: 10/27/2014 12:00:00 AM
Last Editorial Review: 10/28/2014 12:00:00 AM
Whooping Cough Vaccine Rates During Pregnancy Fall Short: CDC
Source: MedicineNet Pertussis Specialty [2014.09.26]
Title: Whooping Cough Vaccine Rates During Pregnancy Fall Short: CDC
Category: Health News
Created: 9/25/2014 4:36:00 PM
Last Editorial Review: 9/26/2014 12:00:00 AM
Published Studies Related to Hydromet (Hydrocodone / Homatropine)
Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers. [2003.01]
RATIONALE: The subjective, psychomotor, and physiological effects of prescription compounds containing the opioid hydrocodone have not been studied in a population of non-drug-abusing people who might be prescribed these compounds for cough or pain relief. OBJECTIVES: To characterize the effects of a hydrocodone combination product, Hycodan, which contains hydrocodone and a peripherally-acting anticholinergic, homatropine, in non-drug-abusing volunteers... CONCLUSIONS: Hycodan at the highest dose tested had effects similar to that of a prototypic mu agonist, morphine. Both drugs produced pleasant (including drug liking) as well as unpleasant subjective effects. Post-session ratings of overall liking and "want to take drug again" were not significant.
Clinical Trials Related to Hydromet (Hydrocodone / Homatropine)
Pharmacokinetics and Bioequivalence of Vycavert (10 mg Hydrocodone Bitartrate/325 mg Acetaminophen) Compared to the Reference Drug Norco [Recruiting]
This study aims to determine whether the hydrocodone and acetaminophen exposures following
oral dosing of Vycavert are comparable to those following oral dosing of Norco.
A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment [Recruiting]
The purpose of this study is:
1. To assess the pharmacokinetics of the hydrocodone bitartrate extended-release tablet in
subjects with moderate hepatic impairment and in subjects with normal hepatic function.
2. To assess the safety and tolerability of the hydrocodone bitartrate extended-release
tablet in subjects with moderate hepatic impairment and in subjects with normal hepatic
A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet [Recruiting]
The primary objective of this study is to assess the bioequivalence of two 45-mg hydrocodone
bitartrate extended-release tablets and one 90-mg hydrocodone bitartrate extended-release
Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain [Recruiting]
The primary objective of this study is to evaluate the analgesic efficacy and safety of HYD
tablets 20 to 120 mg once-daily dose compared to placebo in subjects with moderate to severe
chronic low back pain uncontrolled by their current stable analgesic regimen
Hydrocodone For Pain Control in First Trimester Surgical Abortion [Recruiting]
The purpose of this study is to determine whether preoperatively administered
hydrocodone/acetaminophen (HC/APAP) reduces pain during a first trimester surgical abortion.